Status:
UNKNOWN
Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Cancer
Pain
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In the current research the investigators would like to examine the effect of a well acquainted drug, Ketamine, which is used by anesthesiologists to induce sleep in operations. Usually the ketamine i...
Detailed Description
It is estimated that 10%-15% of patients with cancer-related pain do not achieve acceptable levels of pain relief even when oral or parenteral opioids are skillfully combined with conventional adjuvan...
Eligibility Criteria
Inclusion
- 1\. Patient suffering from severe cancer pain (VAS\>6 at rest or on movement) despite the opioid treatment.
- 2\. Opiate tolerance suspected on the basis of rapid escalation in opiate dose 3. Severe opiate side effects
Exclusion
- 1\. Recent psychiatric hospitalization, suicide attempt, or history within the preceding month of electroconvulsive therapy 2. History of psychosis, eg, schizophrenia 3. History of recent seizures 4. Uncontrolled intracranial hypertension due to brain metastasis or hydrocephalus 5. Severe labile hypertension or poorly controlled cardiac arrhythmia 6. Chronic obstructive pulmonary disease (COPD) associated with hypercarbia
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2012
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01207206
Start Date
October 1 2010
End Date
October 1 2012
Last Update
November 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Sourasky Medical Center, Pain Medicine Unit
Tel Aviv, Israel